Genetic variation at the synaptic vesicle gene SV2A is associated with schizophrenia

Schizophrenia Research

Volumn 141, Issue 2-3, 2012, Pages 262-265

  Mattheisen, Manuel ^a,b   Mühleisen, Thomas W ^a   Strohmaier, Jana ^c   Treutlein, Jens ^c   Nenadic, Igor ^d   Alblas, Margrieta ^a   Meier, Sandra ^c   Degenhardt, Franziska ^a   Herms, Stefan ^a   Hoffmann, Per ^a   Witt, Stephanie H ^c   Giegling, Ina ^e,i   Sauer, Heinrich ^d   Schulze, Thomas G ^f   Rujescu, Dan ^e,i   Nöthen, Markus M ^a,g   Rietschel, Marcella ^c   Cichon, Sven ^a,h  

^a UNIVERSITY OF BONN   (Germany)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d JENA UNIVERSITY HOSPITAL   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f UNIVERSITY OF GÖTTINGEN   (Germany)

^g GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^h FORSCHUNGSZENTRUM JÜLICH   (Germany)

ⁱ MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Candidate gene; GABA; Neuropsychiatric disorder; Single nucleotide polymorphism; Synapse

Indexed keywords

BETA1 INTEGRIN; BRAIN PROTEIN; SYNAPTIC VESICLE GLYCOPROTEIN 2A; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHROMOSOME 1; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GENE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GERMANY; HAPLOTYPE MAP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SYNAPSE VESICLE; SYNAPTIC VESICLE GLYCOPROTEIN 2A GENE;

ADULT; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GERMANY; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA;

EID: 84866907367     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.08.027     Document Type: Article

References (28)

1. Aggarwal A., Sharma D.D., Sharma R.C., Kumar R. Probable psychosis associated with levetiracetam: a case report. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35(1):274-275.
2. Akbarian S. The molecular pathology of schizophrenia - focus on histone and DNA modifications. Brain Res. Bull. 2010, 83(3-4):103-107.
3. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21(2):263-265.
4. Benes F.M., Lim B., Matzilevich D., Walsh J.P., Subburaju S., Minns M. Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(24):10164-10169.
5. Crowder K.M., Gunther J.M., Jones T.A., Hale B.D., Zhang H.Z., Peterson M.R., Scheller R.H., Chavkin C., Bajjalieh S.M. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc. Natl. Acad. Sci. U. S. A. 1999, 96(26):15268-15273.
6. Dardou D., Dassesse D., Cuvelier L., Deprez T., De Ryck M., Schiffmann S.N. Distribution of SV2C mRNA and protein expression in the mouse brain with a particular emphasis on the basal ganglia system. Brain Res. 2011, 1367:130-145.
7. Dong E., Nelson M., Grayson D.R., Costa E., Guidotti A. Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(36):13614-13619.
8. Gabriel S.B., Schaffner S.F., Nguyen H., Moore J.M., Roy J., Blumenstiel B., Higgins J., DeFelice M., Lochner A., Faggart M., Liu-Cordero S.N., Rotimi C., Adeyemo A., Cooper R., Ward R., Lander E.S., Daly M.J., Altshuler D. The structure of haplotype blocks in the human genome. Science 2002, 296(5576):2225-2229.
9. Grunze H., Langosch J., Born C., Schaub G., Walden J. Levetiracetam in the treatment of acute mania: an open add-on study with an on-off-on design. J. Clin. Psychiatry 2003, 64(7):781-784.
10. International HapMap Consortium A haplotype map of the human genome. Nature 2005, 426(6968):789-796.
11. Johnson A.D., Handsaker R.E., Pulit S.L., Nizzari M.M., O'Donnell C.J., de Bakker P.I. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 2008, 24(24):2938-2939.
12. Kasai T., Inoue M., Koshiba S., Yabuki T., Aoki M., Nunokawa E., Seki E., Matsuda T., Matsuda N., Tomo Y., Shirouzu M., Terada T., Obayashi N., Hamana H., Shinya N., Tatsuguchi A., Yasuda S., Yoshida M., Hirota H., Matsuo Y., Tani K., Suzuki H., Arakawa T., Carninci P., Kawai J., Hayashizaki Y., Kigawa T., Yokoyama S. Solution structure of a BolA-like protein from Mus musculus. Protein Sci. 2004, 13(2):545-548.
13. Kinrys G., Worthington J.J., Wygant L., Nery F., Reese H., Pollack M.H. Levetiracetam as adjunctive therapy for refractory anxiety disorders. J. Clin. Psychiatry 2007, 68(7):1010-1013.
14. Kuehn B.M. FDA warns of adverse events linked to smoking cessation drug and antiepileptics. JAMA 2008, 299(10):1121-1122.
15. Lichtenstein P., Yip B.H., Björk C., Pawitan Y., Cannon T.D., Sullivan P.F., Hultman C.M. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 2009, 373(9659):234-239.
16. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(26):9861-9866.
17. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988, 16(3):1215.
18. Mudge J., Miller N.A., Khrebtukova I., Lindquist I.E., May G.D., Huntley J.J., Luo S., Zhang L., van Velkinburgh J.C., Farmer A.D., Lewis S., Beavis W.D., Schilkey F.D., Virk S.M., Black C.F., Myers M.K., Mader L.C., Langley R.J., Utsey J.P., Kim R.W., Roberts R.C., Khalsa S.K., Garcia M., Ambriz-Griffith V., Harlan R., Czika W., Martin S., Wolfinger R.D., Perrone-Bizzozero N.I., Schroth G.P., Kingsmore S.F. Genomic convergence analysis of schizophrenia: mRNA sequencing reveals altered synaptic vesicular transport in post-mortem cerebellum. PLoS One 2008, 3(11):e3625.
19. Muralidharan A., Bhagwgar Z. Potential of levetiracetam in mood disorders: a preliminary review. CNS Drugs 2006, 20(12):969-979.
20. Nowack A., Yao J., Custer K.L., Bajjalieh S.M. SV2 regulates neurotransmitter release via multiple mechanisms. Am. J. Physiol. Cell Physiol. 2010, 299(5):C960-C967.
21. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A.R., Bender D., Maller J., Sklar P., de Bakker P.I.W., Daly M.J., Sham P.C. PLINK: a toolset for whole-genome association and population-based linkage analysis. Am. J. Hum. Genet. 2007, 81(3):559-575.
22. Rietschel M., Mattheisen M., Degenhardt D., GROUP Investigators, Mühleisen M., Kirsch P., Esslinger C., Herms S., Demontis D., Steffens M., Strohmaier J., Haenisch B., Breuer R., Czerski P.M., Giegling I., Strengman E., Schmael C., Mors O., Mortensen P.B., Hougaard D.M., Ørntoft T., Kapelski P., Priebe L., Basmanav F.B., Forstner A.J., Hoffmann P., Meier S., Moebus S., Alexander M., Mössner R., Wichmann H.E., Schreiber S., Rivandeneira F., Hofman A., Uitterlinden A.G., Wienker T.F., Schumacher J., Hauser J., Maier W., Cantor R.M., Erk S., Schulze T.G., SGENE-plus consortium, Craddock N., Owen M.J., O'Donovan M.C., Børglum A.D., Rujescu D., Walter H., Meyer-Lindenberg A., Nöthen M.M., Ophoff R.A., Cichon S. Association between genetic variation in a region on chromosome 11 and schizophrenia in large samples from Europe. Mol. Psychiatry 2012, 17(9):906-917. (Electronic publication ahead of print 2011 Jul 12). 10.1038/mp.2011.80.
23. Ripke S., Sanders A.R., Kendler K.S., Levinson D.F., Sklar P., Holmans P.A., Lin D.Y., Duan J., Ophoff R.A., Andreassen O.A., Scolnick E., Cichon S., St Clair D., Corvin A., Gurling H., Werge T., Rujescu D., Blackwood D.H., Pato C.N., Malhotra A.K., Purcell S., Dudbridge F., Neale B.M., Rossin L., Visscher P.M., Posthuma D., Ruderfer D.M., Fanous A., Stefansson H., Steinberg S., Mowry B.J., Golimbet V., De Hert M., Jönsson E.G., Bitter I., Pietiläinen O.P., Collier D.A., Tosato S., Agartz I., Albus M., Alexander M., Amdur R.L., Amin F., Bass N., Bergen S.E., Black D.W., Børglum A.D., Brown M.A., Bruggeman R., Buccola N.G., Byerley W.F., Cahn W., Cantor R.M., Carr V.J., Catts S.V., Choudhury K., Cloninger C.R., Cormican P., Craddock N., Danoy P.A., Datta S., de Haan L., Demontis D., Dikeos D., Djurovic S., Donnelly P., Donohoe G., Duong L., Dwyer S., Fink-Jensen A., Freedman R., Freimer N.B., Friedl M., Georgieva L., Giegling I., Gill M., Glenthøj B., Godard S., Hamshere M., Hansen M., Hansen T., Hartmann A.M., Henskens F.A., Hougaard D.M., Hultman C.M., Ingason A., Jablensky A.V., Jakobsen K.D., Jay M., Jürgens G., Kahn R.S., Keller M.C., Kenis G., Kenny E., Kim Y., Kirov G.K., Konnerth H., Konte B., Krabbendam L., Krasucki R., Lasseter V.K., Laurent C., Lawrence J., Lencz T., Lerer F.B., Liang K.Y., Lichtenstein P., Lieberman J.A., Linszen D.H., Lönnqvist J., Loughland C.M., Maclean A.W., Maher B.S., Maier W., Mallet J., Malloy P., Mattheisen M., Mattingsdal M., McGhee K.A., McGrath J.J., McIntosh A., McLean D.E., McQuillin A., Melle I., Michie P.T., Milanova V., Morris D.W., Mors O., Mortensen P.B., Moskvina V., Muglia P., Myin-Germeys I., Nertney D.A., Nestadt G., Nielsen J., Nikolov I., Nordentoft M., Norton N., Nöthen M.M., O'Dushlaine C.T., Olincy A., Olsen L., O'Neill F.A., Orntoft T.F., Owen M.J., Pantelis C., Papadimitriou G., Pato M.T., Peltonen L., Petursson H., Pickard B., Pimm J., Pulver A.E., Puri V., Quested D., Quinn E.M., Rasmussen H.B., Réthelyi J.M., Ribble R., Rietschel M., Riley B.P., Ruggeri M., Schall U., Schulze T.G., Schwab S.G., Scott R.J., Shi J., Sigurdsson E., Silverman J.M., Spencer C.C., Stefansson K., Strange A., Strengman E., Stroup T.S., Suvisaari J., Terenius L., Thirumalai S., Thygesen J.H., Timm S., Toncheva D., van den Oord E., van Os J., van Winkel R., Veldink J., Walsh D., Wang A.G., Wiersma D., Wildenauer D.B., Williams H.J., Williams N.M., Wormley B., Zammit S., Sullivan P.F., O'Donovan M.C., Daly M.J., Gejman P.V., Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium Genome-wide association study identifies five new schizophrenia loci. Nat. Genet. 2011, 43(10):969-976.
24. Saha S., Chant D., Welham J., McGrath J. A systematic review of the prevalence of schizophrenia. PLos Med. 2005, 2(5):413-433.
25. Sullivan P.F., Kendler K.S., Neale M.C. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch. Gen. Psychiatry 2003, 60(12):1187-1192.
26. Treutlein J., Mühleisen T.W., Frank J., Mattheisen M., Herms S., Ludwig K.U., Treutlein T., Schmael C., Strohmaier J., Bösshenz K.V., Breuer R., Paul T., Witt S.H., Schulze T.G., Schlösser R.G., Nenadic I., Sauer H., Becker T., Maier W., Cichon S., Nöthen M.M., Rietschel M. Dissection of phenotype reveals possible association between schizophrenia and Glutamate Receptor Delta 1 (GRID1) gene promotor. Schizophr. Res. 2009, 111(1-3):123-130.
27. Van Snellenberg J.X., de Candia T. Meta-analytic evidence for familial coaggregation of schizophrenia and bipolar disorder. Arch. Gen. Psychiatry 2009, 66(7):748-755.
28. White J.R., Walczak T.S., Leppik I.E., Rarick J., Tran T., Beniak T.E., Matchinsky D.J., Gumnit R.J. Discontinuation of levetiracetam because of behavioral side effects. A case-control study. Neurology 2003, 61(9):1218-1221.